Advertisement

Platelet Deposition in Renal Transplant Rejection and Treatment with Prostacyclin Infusion

  • M. Schwarz
  • Ch. Leithner
  • H. Sinzinger

Abstract

Platelet deposition on vascular endothelium is well known to play a key role in transplant rejection. Colman and co-workers1 and Smith and co-workers2 have described this phenomenon in acute and subacute rejection, whereas Leithner and coworkers3 observed platelet deposition by a radioisotopic method in the majority of patients suffering from chronic rejection too.

Keywords

Blood Urea Nitrogen Acute Rejection Plasma Creatinine Chronic Rejection Transplant Rejection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Colman RW, Braun WE, Busch GJ, et al: Coagulation studies in the hyperacute and other forms of renal-allograft rejection. N Engl J Med 281: 685–691, 1969.PubMedCrossRefGoogle Scholar
  2. 2.
    Smith N, Chandler S, Hawker LM, et al: Indium labelled autologous platelets as diagnostic aid after renal transplantation. Lancet ii: 1241–1242, 1979.Google Scholar
  3. 3.
    Leithner C, Sinzinger H, Angelberger P, et al: Indium-111 labelled platelets in chronic kidney transplant rejection. Lancet ií: 213–214, 1980.Google Scholar
  4. 4.
    Ross R, Glomset J, Kariya B, et al: A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Nat Acad Sci USA 71: 1207–1210, 1974.PubMedCrossRefGoogle Scholar
  5. 5.
    Mundy AR, Bewick M, Moncada S, et al: Short term suppression of hyperacute renal allograft rejection in presensitized dogs with prostacyclin. Prostaglandins 19: 595–604, 1980.PubMedCrossRefGoogle Scholar
  6. 6.
    Moncada S, Higgs EA, Vane JR: Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet i: 18–20, 1977.Google Scholar
  7. 7.
    Gerber JG, Nies AS, Friesinger GC, et al: The effect of PGI2 on canine renal function and haemodynamics. Prostaglandins 16: 519–528, 1978.Google Scholar
  8. 8.
    Szczeklik A, Nizankowski R, Skawinski S, et al: Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet i:1111–1113, 1979.Google Scholar
  9. 9.
    Turney JH, Williams LC, Fewell MR, et al: Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet ii: 219–222, 1980.Google Scholar
  10. 10.
    Hume DM, Merrill JP, Miller BF, et al: Experiences with renal homotransplantation in the human: Report of nine cases. J Clin Invest 34: 327–382, 1955.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1983

Authors and Affiliations

  • M. Schwarz
    • 1
  • Ch. Leithner
    • 1
  • H. Sinzinger
    • 1
  1. 1.Second Department of Internal MedicineUniversity of ViennaViennaAustria

Personalised recommendations